Can a biomarker test unlock better treatment for Right-Sided colon cancer?

NCT ID NCT07094893

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 4 trial is for people with advanced colorectal cancer that started on the right side of the colon and has a normal RAS gene. Researchers want to see if adding the targeted drug cetuximab to standard chemotherapy helps shrink tumors more than chemotherapy alone or with bevacizumab. The study will also check if a biomarker test (EREG/AREG) can predict who benefits most. About 280 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cetuximab (anti-EGFR drug) combined with chemotherapy (irinotecan, oxaliplatin, 5-FU, capecitabine) and/or bevacizumab
What this could lead to
If successful, this could show that a biomarker test (EREG/AREG) helps identify which patients with right-sided colon cancer benefit from adding cetuximab to standard chemotherapy, potentially improving tumor shrinkage and survival.
What could go wrong
This trial is not yet recruiting and is relatively small (280 participants). The benefit may be limited to a specific biomarker subgroup, and anti-EGFR drugs can cause skin reactions and other side effects. Results may not apply to all colorectal cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.